Public Health & Access
HIV prevention uptake rises but coverage gaps remain
What’s happening
Use of Gilead’s HIV prevention shot is rising in the U.S., but insurance coverage gaps continue to limit broader adoption.
What’s changing / Business impact
-
Growth in: preventive care demand.
-
Opportunity for: HIV drugmakers.
-
Pressure on: insurers to expand coverage.
Why this matters
Preventive healthcare adoption is increasing.
Access remains constrained by payer systems.